+34 620 10 75 37info@nanbiosis.com

Singular

Singular

You are here : Home / Singular (Page 6)

U2-S05. Monoclonal Antibody development

Monoclonal Antibody development

To develop customized monoclonal antibodies, we adapt our protocols at each critical stage of antibody production. This includes designing the antigen, immunization protocol, and screening design of hybridoma cell supernatants. The initial step involves immunizing mice or rats with a specific antigen. We can develop monoclonal antibodies against various antigen types, such as proteins, peptides, small molecules, or cells. The immunization process typically spans 10-12 weeks. The animal with the most robust immune response undergoes a final immunization to stimulate antibody-producing cells. Spleen cells are isolated and fused with immortal myeloma cell lines to create hybridoma cells. The chosen hybridoma clones are then subcloned to ensure cell stability and maintain their monoclonal characteristics. Finally, the isolated cells are expanded and cryopreserved.

Customer benefits

  • Versatility: Monoclonal antibodies can be used in diagnostics, therapeutics, and research.
  • Customization: Protocols can be adapted to meet specific needs
  • Quality Assurance: Our processes adhere to the ISO 9001 quality requirements.

Target customer

  • Organizations involved in research and development, pharmaceutical companies, academic institutions, and diagnostic laboratories benefit from monoclonal antibody development.
  • Researchers studying diseases, drug targets, and immune responses rely on mAbs for their work.

Additional information

Monoclonal antibody development workflow

Selected references:

  • Giovanna Roncador; Pablo Engel; Lorena Maestre; et al; Alison H.Banham., Nuria Pascual 2016. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. Taylor & Francis Online. 8-1, pp.27-36
  • Rodriguez-Urretavizcaya, N. Pascual, C. Pastells, M. T. Martin-Gomez, Ll. Vilaplana, M.-P. Marco. Diagnostic and Stratification of Pseudomonas aeruginosa Infected Patients by Immunochemical Quantitative Determination of Pyocyanin from Clinical Bacterial Isolates. Frontiers in Cell. Infect. Microbiol., 11, 786929, 2021. DOI: 10.3389/fcimb.2021.786929
• Read More

U2-S04. Polyclonal Antibody Production

Polyclonal Antibody Production

Firstly, your project is discussed with our team, we help you to make the right decisions and personalize the process according to your goals. For the production of polyclonal antibodies, we select New Zealand white rabbits. Additionally, we offer the development of polyclonal antibodies in mice and rats.
We can generate policlonal antibodies towards a variety of antigens including small molecules, peptides, proteins, and cells.
Our standard immunization protocol includes monthly inoculations with Freund’s adjuvant over a 6-month period. To assess immune response progress, blood samples are taken 10 days after the second inoculation to obtain serum and determine antibody titers using ELISA. Preimmune serum is collected before the first injection for controls. At the end of the process, complete blood collection from the animal is performed surgically under anesthesia, resulting in 50-70 mL of hyperimmune serum per animal. The service provides 5 mL of bleed serum from each test for screening in customer labs.
We can follow your personalized immunization program in addition to our well-established ones.

Customer benefits

  • Scientific Consultation: We provide thorough consultation before the project begins.
  • Customized Project Proposals: We tailor project proposals to meet your specific requirements.
  • Flexible Workflow: Adjustments can be made to the workflow based on results and your specific requests.

Target customer

Organizations involved in research and development, particularly those seeking reliable and customized polyclonal antibody development services, will find our offering essential for their scientific endeavors.

Additional information

Selected references:

  • E. Montagut, J. Raya, M.-T. Martín Gómez, L. Vilaplana, B. Rodríguez-Urretavizcaya, M.-P. Marco. An Immunochemical Approach to detect the Quorum Sensing-Regulated Virulence Factor 2-Heptyl-4-Quinoline N-Oxide (HQNO) produced by Pseudomonas aeruginosa Clinical Isolates. Microbiol. Spect., 10(4), 1-12, 2022
  • E. Montagut, G. Acosta, F. Albericio, M. Royo, G. Godoy-Tena, A. Lacoma, C. Prat, J.-P. Salvador, M.-P. Marco. Direct Quantitative Immunochemical Analysis of the Autoinducer Peptide IV (AIP-IV) for Diagnosing and Stratifying Staphylococcus aureus infections. ACS Infect. Dis., 8(3), 645-656, 2022.
  • ­G. Colom, J.-P. Salvador, G. Acosta, M. Royo, M.-P. Marco. Competitive ELISA for N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) determination in human plasma. Analyst, 145, 6719-6727, 2020.
• Read More

U2-S03. Preparation of Bioconjugates and Molecular Probes

Preparation of Bioconjugates and Molecular Probes

The preparation of bioconjugates and molecular probes involves a diverse array of techniques and strategies aimed at functionalizing biomolecules for various applications. This process encompasses the labeling of antibodies, haptenized proteins, and enzymes, as well as the biotinylation and fluorescent labeling of probes, and the conjugation of biomolecules with nanoparticles and other entities.

Customer benefits

  • To develop antibodies against small molecules (preparation of immunization bioconjugate)
  • Enhanced Functionality: Bioconjugation allows for specific binding of biomolecules, such as antibodies or peptides, to other entities like molecular probes or nanoparticles. This expands the applications and functionalities of biomolecules.
  • Improved Sensitivity and Specificity: Bioconjugates can enhance the sensitivity and specificity of detection techniques, such as immunohistochemistry or flow cytometry.
  • Diverse Applications: Bioconjugates find application in research, diagnostics, and therapy, benefiting research laboratories, hospitals, and pharmaceutical companies.

Target customer

  • Researchers and Scientists: Satisfy the need to label biomolecules for research studies.
  • Pharmaceutical and Biotechnology Companies: For creating therapeutic bioconjugates, imaging markers or bioconjugates for immunizations of non-immunogenic small molecules, between other.

Additional information

Selected references:

  • E. Montagut, J. Raya, M.-T. Martín Gómez, L. Vilaplana, B. Rodríguez-Urretavizcaya, M.-P. Marco. An Immunochemical Approach to detect the Quorum Sensing-Regulated Virulence Factor 2-Heptyl-4-Quinoline N-Oxide (HQNO) produced by Pseudomonas aeruginosa Clinical Isolates. Microbiol. Spect., 10(4), 1-12, 2022.
  • B. Rodriguez-Urretavizcaya, N. Pascual, C. Pastells, M. T. Martin-Gomez, Ll. Vilaplana, M.-P. Marco. Diagnostic and Stratification of Pseudomonas aeruginosa Infected Patients by Immunochemical Quantitative Determination of Pyocyanin from Clinical Bacterial Isolates. Frontiers in Cell. Infect. Microbiol., 11, 786929, 2021. DOI: 10.3389/fcimb.2021.786929.
  • J. Marrugo-Ramírez, M. Rodríguez-Núñez, M.-P Marco, M. Mir, J. Samitier. Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer’s Disease. Biosensors, 11(1), 20, 2021.
  • E. J. Montagut, Ll. Vilaplana, M.T. Martin-Gómez, M.-P. Marco. A High Throughput Immunochemical Method to Assess 2-Heptyl-4-Quinolone Quorum Sensing Molecule as Potential Biomarker. ACS Infect. Dis., 6(12), 3237-3246, 2020.
  • M. Broto, R. McCabe, R. Galve, M.-P. Marco. A high-specificity immunoassay for the therapeutic drug monitoring of ciclophosphamide. Analyst, 144, 5172-5178, 2019.
• Read More

U2-S02. Hapten design and synthesis

Hapten design and synthesis

Haptens are small molecules capable of eliciting an immune response when conjugated to a carrier protein. They serve as antigens for antibody production. The service designs and produces tailored haptens to match the target analyte, ensuring the desired features of the resulting antibody.

This process includes:

  • Selecting the most suitable position on a drug molecule to attach a linker, maximizing specificity, sensitivity, and immunogenicity of the immunogen
  • Performing total synthesis to create the hapten with a linker when the parent drug molecule lacks a functional group suitable for conjugation synthesis.
  • Designing and synthesizing the linker with the optimal length.

Customer benefits

Some specific advantages that customers gain by utilizing this service include:

  • Adaptation of haptens to meet specific customer needs.
  • Production of highly specific and  antibodies.
  • Added value in research and development by obtaining personalized immunological tools.
  • Essential for organizations involved in drug discovery, diagnostics, and therapy.

Target customer

Target customer Researchers, scientists, and professionals involved in research and development in various fields including food safety and environmental control, biomedicine, diagnostics, drug discovery, and therapeutic development.

Additional information

Selected references:

  • E. Montagut, J. Raya, M.-T. Martín Gómez, L. Vilaplana, B. Rodríguez-Urretavizcaya, M.-P. Marco. An Immunochemical Approach to detect the Quorum Sensing-Regulated Virulence Factor 2-Heptyl-4-Quinoline N-Oxide (HQNO) produced by Pseudomonas aeruginosa Clinical Isolates. Microbiol. Spect., 10(4), 1-12, 2022.
  • B. Rodriguez-Urretavizcaya, N. Pascual, C. Pastells, M. T. Martin-Gomez, Ll. Vilaplana, M.-P. Marco. Diagnostic and Stratification of Pseudomonas aeruginosa Infected Patients by Immunochemical Quantitative Determination of Pyocyanin from Clinical Bacterial Isolates. Frontiers in Cell. Infect. Microbiol., 11, 786929, 2021. DOI: 10.3389/fcimb.2021.786929.
  • J. Marrugo-Ramírez, M. Rodríguez-Núñez, M.-P Marco, M. Mir, J. Samitier. Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer’s Disease. Biosensors, 11(1), 20, 2021.
  • E. J. Montagut, Ll. Vilaplana, M.T. Martin-Gómez, M.-P. Marco. A High Throughput Immunochemical Method to Assess 2-Heptyl-4-Quinolone Quorum Sensing Molecule as Potential Biomarker. ACS Infect. Dis., 6(12), 3237-3246, 2020.
  • M. Broto, R. McCabe, R. Galve, M.-P. Marco. A high-specificity immunoassay for the therapeutic drug monitoring of ciclophosphamide. Analyst, 144, 5172-5178, 2019.
• Read More

U27-S01. Remote access to HPC

Remote access to HPC

The HPC service allows remote access to High Performance Computing, Massive Parallel Processing, Mass Storage and different software applications. Designed to meet the demands of projects requiring exceptional computational performance, our service provides users with the flexibility and power to address a wide variety of challenges. It responds to the increasing complexity of simulations carried out by the most advanced research projects.

Customer benefits

The “Remote Access to Infrastructure with Massively Parallel Processing in HPC” service offers our clients distinctive advantages that not only meet their requirements but also add significant value to their Research and Development projects. 

  • Exceptional Performance: We provide our clients with access to cutting-edge HPC infrastructure, ensuring exceptional computational performance. 
  • Flexibility for Various Applications: Our service is generic and highly adaptable, satisfying a wide variety of R&D applications. 
  • Elimination of Geographic Restrictions: By offering secure remote access to our infrastructure, we eliminate geographic limitations.

Essential Scenarios:

  • Cutting-edge Scientific Research: Our service is essential for projects that require significant computational power, such as detailed molecular dynamics simulations, biomedical and biochemical modeling, simulations of all types, etc. 
  • Development of High-Performance Algorithms: our service is crucial for testing and optimizing high-performance algorithms, ensuring efficient execution in production environments. 
  • Complex Data Analysis and Big Data: In projects that involve the analysis of large data sets, from genomic sequencing to artificial intelligence, our service allows for massively parallel processing, improving the speed and accuracy of the analysis.

Target customer

The service is designed to meet the specific needs of diverse user groups, allowing them to take full advantage of massively parallel processing capabilities. 

  • Scientific Researchers and Academics: We provide access to cutting-edge HPC infrastructure, allowing them to perform advanced simulations, complex modeling and data analysis at a scale that goes beyond the capabilities of conventional systems. 
  • High Performance Software Development Teams: Intensive algorithms and high-performance applications, we offer a scalable platform that facilitates extensive testing and optimization to ensure optimal performance. 
  • Biomedical Research Institutions: can leverage our infrastructure for the analysis of large data sets, detailed simulations and complex studies, driving significant advances in the understanding of diseases and the development of therapies. 
  • Artificial Intelligence and Machine Learning teams: can leverage our infrastructure for training complex models and analyzing massive data sets.

Additional information

The HPC service has more than 3260 cores and 5920 parallel processing threads, 26TB of RAM, 264TB NVMe and 400TB HDD of shared storage, all connected by a 100Gbps backbone network. In addition, we currently offer 251,392 CUDA cores, 720GB graphics memory, 1,179.42 peak FP16 TFLOPS, and 828.6 peak FP32 TFLOPS.

• Read More

U27-S02. Software installation on demand

Software installation on demand

This Unit offers an exceptional software installation service that is not present in our infrastructure. We study each case to try to find the best solution, as long as it fits the technical characteristics, both hardware and software of the Unit.

• Read More

U27-S03. Biomedical signals processing

Biomedical signals processing

In our continued commitment to providing advanced solutions in High-Performance Computing (HPC), we are proud to present our specialized service in “Biomedical Signal Processing”. This service harnesses the power of high-performance computing to facilitate the analysis and interpretation of biomedical signals, offering advanced solutions for a variety of clinical and research scenarios.
The HPC service allows remote access to High Performance Computing, Massive Parallel Processing, Mass Storage and different software applications. It responds to the increasing complexity of simulations carried out by the most advanced research projects.

Customer benefits

The “Biomedical Signal Processing” service offers our clients specific advantages by providing access to our advanced High-Performance Computing (HPC) infrastructure, adding significant value to your Research and Development (R&D) activities. Focusing on the critical scenarios in where our service becomes essential, we highlight the following advantages: 

  • Validation of Theoretical Models: We allow researchers to validate and adjust theoretical organ models through detailed simulations, using computing power to compare theoretical results with experimental data. 
  • Custom Algorithm Development: Researchers and scientists can leverage HPC infrastructure to develop and refine custom signal processing algorithms tailored to their specific research objectives. 
  • Analysis of Large Data Sets: For projects involving the analysis of large data sets of biomedical signals, we offer the processing power necessary to perform detailed evaluations and extract meaningful patterns.

Target customer

Access to our HPC infrastructure is designed to meet the needs of diverse user groups, allowing them to perform specialized calculations and experiments in the field of biomedical signal processing.

  • Researchers and Scientists: We offer biomedical engineering  researchers access to HPC resources to perform advanced simulations, validate theoretical models and explore new perspectives in the diagnosis and treatment of cardiac diseases.
  • Biomedical Algorithm Developers: For those focused on developing and refining specific signal processing algorithms, we provide the necessary infrastructure to implement and evaluate custom algorithms.
  • Healthcare Professionals and Biomedical Engineers: Healthcare professionals and biomedical engineers can use our HPC platform to analyze and process large signal data sets, improving efficiency in the analysis of clinical information and the development of advanced medical technologies.
  • Biomedical Technology Companies: We provide them with the ability to test and validate their products in simulated environments, optimizing the performance and precision of their solutions.

Additional information

The HPC service has more than 3260 cores and 5920 parallel processing threads, 26TB of RAM, 264TB NVMe and 400TB HDD of shared storage, all connected by a 100Gbps backbone network. In addition, we currently offer 251,392 CUDA cores, 720GB graphics memory, 1,179.42 peak FP16 TFLOPS, and 828.6 peak FP32 TFLOPS.

• Read More

U27-S04. Modeling of the functional behaviour of tissues and organs

Modeling of the functional behaviour of tissues and organs

In our continued commitment to providing advanced solutions in High-Performance Computing (HPC), we are pleased to introduce our “Modeling the Functional Behavior of Tissues and Organs” service. This service leverages the power of high-performance computing, massively parallel processing, mass storage and different software applications to provide detailed and accurate analysis of the functional dynamics of tissues and organs.

Customer benefits

Our service significantly reduces work times, moving simulation processes from weeks to days. Additionally, it enables the simulation of different scenarios and parameters simultaneously.

  • Precision and Reliability: Our High-Performance Computing (HPC)-based simulations provide an unmatched level of precision and reliability in modeling the behavior of tissues and organs. This ensures reliable results and high-quality data to inform critical research decisions. 
  • Effective Optimization: By addressing the complexities of biological processes, our service facilitates the optimization of intervention strategies. Organizations can make precise adjustments to treatments and procedures, reducing costs and improving the effectiveness of therapeutic approaches. 
  • Risk Reduction in Development: Through virtual simulations of medical scenarios, organizations can identify and mitigate risks before practical implementation. This is essential in Research and Development, where error reduction and continuous improvement are imperative.

Target customer

Our “Modeling of the Functional Behavior of Tissues and Organs” service is designed to meet the specific needs of various stakeholders engaged in Research and Development, offering solutions adapted to the particular demands of the following key audience:

  • Biomedical and Scientific Researchers: providing them with advanced tools to thoroughly understand the functional behavior of tissues and organs. We facilitate detailed analysis of complex data and simulation of relevant scenarios to drive significant advances in scientific knowledge.
  • Pharmaceutical and Biotechnology Companies: making it easier to obtain detailed information on the response of tissues to specific compounds, accelerating the development process and improving success rates in creating effective treatments.
  • Health Professionals and Clinicians: personalized medicine, facilitating the personalization of treatments, allowing health professionals to adapt interventions according to the individual characteristics of patients. This is particularly valuable in optimizing therapeutic protocols and improving clinical outcomes.
  • Academic Research Institutions: essential for academics and students engaged in the exploration and understanding of biological processes.

Additional information

The HPC service has more than 3260 cores and 5920 parallel processing threads, 26TB of RAM, 264TB NVMe and 400TB HDD of shared storage, all connected by a 100Gbps backbone network. In addition, we currently have 251,392 CUDA cores, 720GB graphics memory, 1,179.42 peak FP16 TFLOPS, and 828.6 peak FP32 TFLOPS.

• Read More

U25-S03. NMR spectrometer 400 MHz with HRMAS/CPMAS probes (Onsite&Remote) OUTSTANDING

NMR spectrometer 400 MHz with HRMAS/CPMAS probes (Onsite&Remote) OUTSTANDING

400 MHz: AVANCE III console, probes 4mm HRMAS BBI 1H/13C/31P/D, with Z-gradients, 4mm MAS VTN 1H/BB for solid-state, and BCU Xtreme unit for sample temperature control

Customer benefits

HRMAS allows for high-resolution NMR spectra of semi-solid and solid samples by spinning the sample at the magic angle, which minimizes broadening due to sample heterogeneity and anisotropic interactions. Also, potential for characterization of polymers, catalysts, porous materials, and nanomaterials, providing insights into molecular structure, dynamics, and interactions. CPMAS NMR is particularly useful for studying crystalline materials, including organic and inorganic compounds, minerals, and pharmaceuticals. It provides information about chemical composition, crystal structure, and molecular dynamics.

Target customer

Researchers or companies with needs to study solid or semisolid samples regarding structure, characterization, interactions or composition.

References

  • Jiménez-Xarrié E, et al. In vivo and ex vivo magnetic resonance spectroscopy of the infarct and the subventricular zone in experimental stroke. J Cereb Blood Flow Metab. 2015 May;35(5):828-34. doi: 10.1038/jcbfm.2014.257. Epub 2015 Jan 21. PMID: 25605287; PMCID: PMC4420856.
  • Delgado-Goñi T, et al. Assessment of a 1H high-resolution magic angle spinning NMR spectroscopy procedure for free sugars quantification in intact plant tissue. Planta. 2013 Aug;238(2):397-413. doi: 10.1007/s00425-013-1924-y. Epub 2013 Jul 4. PMID: 23824526.
  • Martín-Sitjar J, et al. Influence of the spinning rate in the HR-MAS pattern of mobile lipids in C6 glioma cells and in artificial oil bodies. MAGMA. 2012 Dec;25(6):487-96. doi: 10.1007/s10334-012-0327-6. Epub 2012 Jul 20. PMID: 23011574.
  • Valverde-Saubí D, et al. Short-term temperature effect on the HRMAS spectra of human brain tumor biopsies and their pattern recognition analysis. MAGMA. 2010 Sep;23(4):203-15. doi: 10.1007/s10334-010-0218-7. Epub 2010 Jun 13. PMID: 20549297.
  • Simões RV, et al. 1H-MRSI pattern perturbation in a mouse glioma: the effects of acute hyperglycemia and moderate hypothermia. NMR Biomed. 2010 Jan;23(1):23-33. doi: 10.1002/nbm.1421. PMID: 19670263.
• Read More

U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING

Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING

7T Bruker BioSpec 70/30 USR MR system (Bruker BioSpin GmbH, Karlsruhe, Germany) equipped with a BGA12 mini-imaging gradient insert (maximum amplitude: 400 mT/m and slew rate: 5500 T/m/s). Capability for magnetic resonance imaging and spectroscopy of small animals (e.g. mouse, rat) and studies of model solutions (e.g. new contrast agents). Also capabilities for advanced imaging techniques such as diffusion and perfusion weighted images and fractional anisotropy. Coupled with anaesthetic equipment and vital signs monitoring for in vivo experiments.

Customer benefits

Noninvasive studies of anatomy and biochemical environment depending on the organ. Studies of physiological and pathological anatomy changes with a high resolution level. Magnetic resonance is not based on ionizing radiation and can be performed as many times as needed. Assessment of new therapeutic agents efficacy and novel contrast agents potential. T1, T2 and T2* maps measurement.

Target customer

Research groups or companies working with preclinical models, novel therapeutic or contrast agents, characterization of novel preclinical models based in cancer, inflammatory or neurological diseases.

References

  • Zhang S, et al. Metal-Free Radical Dendrimers as MRI Contrast Agents for Glioblastoma Diagnosis: Ex Vivo and In Vivo Approaches. Biomacromolecules. 2022 Jul 11;23(7):2767-2777. doi: 10.1021/acs.biomac.2c00088. Epub 2022 Jun 24. PMID: 35749573; PMCID: PMC9277593.
  • García-Pardo J, et al. Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson’s Disease. ACS Nano. 2021 May 25;15(5):8592-8609. doi: 10.1021/acsnano.1c00453. Epub 2021 Apr 22. PMID: 33885286; PMCID: PMC8558863.
  • Wu S, et al. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images. NMR Biomed. 2020 Apr;33(4):e4229. doi: 10.1002/nbm.4229. Epub 2020 Jan 11. PMID: 31926117.
  • Güell-Bosch J, et al. Progression of Alzheimer’s disease and effect of scFv-h3D6 immunotherapy in the 3xTg-AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy. NMR Biomed. 2020 May;33(5):e4263. doi: 10.1002/nbm.4263. Epub 2020 Feb 17. PMID: 32067292.
  • Suárez-García S, et al. Dual T1/ T2 Nanoscale Coordination Polymers as Novel Contrast Agents for MRI: A Preclinical Study for Brain Tumor. ACS Appl Mater Interfaces. 2018 Nov 14;10(45):38819-38832. doi: 10.1021/acsami.8b15594. Epub 2018 Nov 1. PMID: 30351897.
  • Lope-Piedrafita, S. (2018). Diffusion Tensor Imaging (DTI). In: García Martín, M., López Larrubia, P. (eds) Preclinical MRI. Methods in Molecular Biology, vol 1718. Humana Press, New York, NY. doi: 10.1007/978-1-4939-7531-0_7
  • Arias-Ramos N, et al. Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment. Metabolites. 2017 May 18;7(2):20. doi: 10.3390/metabo7020020. PMID: 28524099; PMCID: PMC5487991.
  • Jiménez-Xarrié E, et al. Brain metabolic pattern analysis using a magnetic resonance spectra classification software in experimental stroke. BMC Neurosci. 2017 Jan 13;18(1):13. doi: 10.1186/s12868-016-0328-x. PMID: 28086802; PMCID: PMC5237280.
• Read More